Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from the Benelux countries Belgium, Luxembourg and The Netherlands or involving organisations from these countries.

Total search results: 1714 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Enzymicals–Syngulon: enzyme production technology, 202005– license non-excl to antibiotic-free selection technology of Syngulon 2020-05-15
OTHER–Enzymicals: enzymes, 202005 service production + supply of diagnostic enzymes using antibiotic-free production for undisclosed world leader 2020-05-15
Polyganics–EU (govt): grant, 202005 EFRO grant €1.2m for clinical development of Liver + Pancreas Sealant Patch 2020-05-13
Polyganics–Instinctif Partners: public relations, 202005 service existent by Instinctif 2020-05-13
Bone Therapeutics–SEVERAL: credit, 202004– bridge loans €4.75m 2020-04-29
Bone Therapeutics–SEVERAL: credit, 202004– fleixble convertibe bonds €4.99m 2020-04-29
Bone Therapeutics–SEVERAL: investment, 202004 private equity placement €1.26m in form of immediate conversion of convertible bonds 2020-04-29
Kurma–EU (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor EIF 2020-04-29
Kurma–Institut Pasteur: investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor Pasteur Institute 2020-04-29
Kurma–North Rhine-Westphalia (govt): investment, 202004 final closing of Kurma Biofund III totalling €160m incl investor NRW.BANK 2020-04-29
Kurma–SEVERAL: investment, 202004 final closing of Kurma Biofund III with €160m 2020-04-29
Robocath–SEVERAL: investment, 202004 financing round Series C €40m led by MicroPort Scientific 2020-04-29
Genedata–Cergentis: genomic software tools, –202004 collab developm of Genedata Selector s/w for automating TLA data analysis workflow 2020-04-28
FoRx Therapeutics–Life Sciences Partners: investment, 202004 seed financing round totalling €10m incl co-investor LSP 2020-04-22
FoRx Therapeutics–Merck (DE): investment, 202004 seed financing round totalling €10m incl co-lead investor M Ventures 2020-04-22
FoRx Therapeutics–SEVERAL: investment, 202004 seed financing round €10m co-led by M Ventures + Novartis Venture Fund + Omega Funds 2020-04-22
Galapagos–Ryvu Therapeutics: anti-inflammatory drugs, 202004– collab r+d small molecules against new target w excl license option for Galapagos 2020-04-16
Centogene–FTI Consulting: public relations, 202004 service existent by FTI Consulting 2020-04-15
Gadeta–Optimum Strategic Communications: public relations, 202004 service existent by Optimum 2020-04-07
iTeos Therapeutics–6 Dimensions Capital: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor 6 Dimensions Capital 2020-04-01
iTeos Therapeutics–Belgium (govt): investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor SFPI 2020-04-01
iTeos Therapeutics–Curative Ventures: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor Curative Ventures 2020-04-01
iTeos Therapeutics–Fund+: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor Fund+ 2020-04-01
iTeos Therapeutics–HBM: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor HBM Partners 2020-04-01
iTeos Therapeutics–Invus Group: investment, 202004 financing round Series B2 totalling $125m incl new + co-investor Invus 2020-04-01
iTeos Therapeutics–Janus Henderson: investment, 202004 financing round Series B2 totalling $125m incl new + co-investor Janus Henderson Investors 2020-04-01
iTeos Therapeutics–MPM Capital: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor MPM Capital 2020-04-01
iTeos Therapeutics–RA Capital Management: investment, 202004 financing round Series B2 totalling $125m incl new + co-lead investor RA Capital 2020-04-01
iTeos Therapeutics–RTW Investments: investment, 202004 financing round Series B2 totalling $125m incl new + co-investor RTW Investments 2020-04-01
iTeos Therapeutics–SEVERAL: investment, 202004 financing round Series B2 $125m co-led by RA Capital Management + Boxer Capital 2020-04-01
iTeos Therapeutics–Tavistock: investment, 202004 financing round Series B2 totalling $125m incl new + co-lead investor Boxer Capital 2020-04-01
iTeos Therapeutics–Univ Leuven: investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor VIVES Louvain Technology Fund 2020-04-01
iTeos Therapeutics–Wallonia (govt): investment, 202004 financing round Series B2 totalling $125m incl existing + co-investor SRIW 2020-04-01
Gilde Investment–SEVERAL: investment, 202003 first + final close of €416m Gilde Healthcare V fund incl investors Philips + Rabo Corp Investments 2020-03-31
Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS 2020-03-10
Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF 2020-03-10
Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical 2020-03-10
Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF 2020-03-10
Bone Therapeutics–Image Box: public relations, 202003– supply service by Image Box PR 2020-03-06
Biotalys–Novalis LifeSciences: investment, 202003 financing round Series C 2nd closing totalling €10m incl new investor Novalis LifeSciences 2020-03-05
Biotalys–SEVERAL: investment, 202003 financing round Series C €10m 2nd closing bringing total Series C to €45m 2020-03-05
Qiagen–Barclays: financial services, 202003 supply service Barclays Bank plc is financial advisor w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–De Brauw Blackstone Westbroek: legal services, 202003 supply service De Brauw BW NV is legal counsel w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Goldman Sachs: financial services, 202003 supply service Goldman Sachs Intl is lead financial advisor w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Linklaters: legal services, 202003 supply service Linklaters LLP is legal counsel w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Mintz Levin Cohn: legal services, 202003 supply service Mintz Levin Cohn FGP is legal counsel w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Thermo Fisher: investment, 202003– acquisition €9.14b cash tender offer at €39/share ANNOUNCED 2020-03-03
Thermo Fisher–JPMorgan Chase: financial services, 202003 supply service JP Morgan Securities LLC is financial advisor w regard to Qiagen acquisition 2020-03-03
Thermo Fisher–Morgan Stanley: financial services, 202003 supply service Morgan Stanley & Co LLC is financial advisor w regard to Qiagen acquisition 2020-03-03
Thermo Fisher–Wachtel Lipton Rosen & Katz: legal services, 202003 legal council to Thermo Fisher with regard to acquisition of Qiagen 2020-03-03
Glycom–DSM: investment, 202002 acquisition of Glycom A/S by DSM for enterprise value of €765m 2020-02-21
OncoDNA–Belgium (govt): investment, 202002 financing round Series B totalling €19m incl significant support from co-investor SFPI-FPIM 2020-02-14
OncoDNA–SEVERAL: investment, 202002 financing round Series B €19m co-led by Vesalius Biocapital III + Swisscanto Invest 2020-02-14
OncoDNA–Vesalius Biocapital: investment, 202002 financing round Series B totalling €19m incl co-lead investor Vesalius Biocapital III 2020-02-14
OncoDNA–Zürcher Kantonalbank: investment, 202002 financing round Series B totalling €19m incl co-lead investor Swisscanto Invest by ZKB 2020-02-14
Azafaros–BioGeneration Ventures: investment, 202002 financing round Series A totalling €25m incl existing + co-investor BiGV 2020-02-06
Azafaros–BioMedPartners: investment, 202002 financing round Series A totalling €25m incl co-investor BioMedPartners 2020-02-06
Azafaros–Forbion: investment, 202002 financing round Series A totalling €25m incl lead investor Forbion 2020-02-06
Azafaros–SEVERAL: investment, 202002 financing round Series A €25m led by Forbion with participation from BioMedPartners + BGV 2020-02-06
Azafaros–Trophic Communications: public relations, 202002 service existent by Trophic Communications 2020-02-06
Catalent–SEVERAL: investment, 202002 underwritten public offering $500m+$75m with approx $330m intented to finance MaSTherCell acquisition 2020-02-03
Orgenesis–Catalent: investment, 202002 acquisition $315m in cash of MaSTherCell Global Inc from Great Point Partners + SFPI-FPIM + Orgenesis Inc 2020-02-03
iTeos Therapeutics–Wallonia (govt): grant?, 202001 non-dilutive funding €11.5m for ph1b/2a of EOS-850 from Walloon Region 2020-01-30
iTeos Therapeutics–Wallonia (govt): grant?, 202001 non-dilutive funding €3.5m for ph1 of EOS-448 from Walloon Region 2020-01-30
iOnctura–SEVERAL: investment, 202001 financing round Series A €15m led by Inkef Capital + co-led by VI Partners 2020-01-23
PDC*line Pharma–SEVERAL: investment, 202001 financing round Series B €13.9m with existing + new investors 2020-01-22
Fibrocor Therapeutics–Galapagos: investment, 202001 equity investment by Galapagos as part of expanded collaboration 2020-01-15
Galapagos–Fibrocor Therapeutics: fibrosis drug, 202001– collab developm expansion excl license option for 4 addit small molecule inhibitor programmes 2020-01-15
Amgen–Qiagen: molecular companion diagnostics, 202002– collab developm KRAS G12C CDx for AMG 510 in NSCLC 2020-01-13
NBE Therapeutics–PPF Group: investment, 202001 financing round Series C totalling $22m incl existing + co-lead investor PPF Group 2020-01-10
NBE Therapeutics–SEVERAL: investment, 202001 financing round Series C USD22m led by existing investors BIVF + PPF Group wih all private investors 2020-01-10
NorthSea Therapeutics–BioGeneration Ventures: investment, 202001 financing round Series B totalling €36m incl existing + co-investor BGV 2020-01-08
NorthSea Therapeutics–Forbion: investment, 202001 financing round Series B totalling €36m incl existing + co-investor Forbion 2020-01-08
NorthSea Therapeutics–New Science Ventures: investment, 202001 financing round Series B totalling €36m incl existing + co-investor NSV 2020-01-08
NorthSea Therapeutics–Novo Group: investment, 202001 financing round Series B totalling €36m incl existing + co-investor Novo Seeds 2020-01-08
NorthSea Therapeutics–SEVERAL: investment, 202001 financing round Series B €36m led by new investor VenBio 2020-01-08
NorthSea Therapeutics–Sofinnova: investment, 202001 financing round Series B totalling €36m incl new + co-investor Sofinnova Investments 2020-01-08
NorthSea Therapeutics–VenBio: investment, 202001 financing round Series B totalling €36m incl new + lead investor VenBio Partners 2020-01-08
Wellington Partners–MC Services: public relations, 202001 service existent by MC Services 2020-01-08
FSHD Unlimited Coop–Evotec: investment, 201912 investment existent Evotec owns 21.12% of voting rights 2019-12-31
Vico Therapeutics–Kurma: investment, 2019Q4c financing round Series A totalling €20m incl investor Kurma Partners 2019-12-31
Vico Therapeutics–Life Sciences Partners: investment, 2019Q4c financing round Series A totalling €20m incl investor LSP 2019-12-31
Vico Therapeutics–SEVERAL: investment, 2019Q4c financing round Series A €20m incl LSP + Kurma Partners 2019-12-31
BioNtech–EU (govt): credit, 201912– EIB/EFSI loan €50m to support cancer therapies r+d 2019-12-17
Augustine Therapeutics–SEVERAL: investment, 201912 seed financing round €4.2m from V-Bio Ventures + PMV + Advent France + Gemma Vrisius + VIB 2019-12-16
Promethera–SEVERAL: investment, 201912 financing round Series D extension €7.5m bringing total round to €47.2m 2019-12-16
ImCheck Therapeutics–Boehringer: investment, 201912 financing round Series B totalling €48m incl existing + co-investor BIVF 2019-12-04
ImCheck Therapeutics–Eurazeo: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Idinvest Partners 2019-12-04
ImCheck Therapeutics–Gimv: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Gimv 2019-12-04
ImCheck Therapeutics–Kurma: investment, 201912 financing round Series B totalling €48m incl existing + co-investor Kurma Partners 2019-12-04
ImCheck Therapeutics–Life Sciences Partners: investment, 201912 financing round Series B totalling €48m incl existing + co-investor LSP 2019-12-04
ImCheck Therapeutics–SEVERAL: investment, 201912 financing round Series B €48m co-led by Bpifrance + Pfizer Ventures 2019-12-04
ECBF–SEVERAL: investment, 201911– European Circular Bioeconomy Fund aims to raise €250m incl up to €100m from EIB 2019-11-29
LabCorp–Qiagen: bioinformatics, 201911– license extension with HGMD in addition ot Qiagen Clinical Insights 2019-11-20
Kuros–SEVERAL: investment, 201911–201912 capital increase CHF12.5m with 6.405m new registered shares at CHF1.95/share 2019-11-19
Zelluna–Glycostem Therapeutics: cell therapy contract manufacturing, 201911– collab developm + supply of TCR-guided NK-cell therapies 2019-11-19
Acticor Biotech–SEVERAL: investment, 201911 financing round Series B extension €7m led by new investorGO Capital bringing Series B to €22.3m 2019-11-06
Argenx–SEVERAL: investment, 201911 global offering $557m with 4.6m ordinary shares incl in the form of ADSs 2019-11-06
AVCare–Acticor Biotech: investment, 201911 acquisition 100% of AVCare by Acticor Biotech 2019-11-06
Centogene–SEVERAL: investment, 201910–201911 IPO $56m+$8.4m with 4m+600k comon shares at $14/share at Nasdaq Global Market 2019-10-28
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top